EU"s pandemic response shortcomings revealed by auditors

The European Court of Auditors reported that the EU's medical agencies were inadequately prepared for the Covid-19 pandemic, highlighting significant shortcomings in their initial responses. The European Centre for Disease Prevention and Control (ECDC) underestimated the seriousness of the virus and was slow to share critical risk assessments and public guidance, such as recommendations on face masks and contact tracing. This delay contributed to a fragmented response across member states, as data on infection rates relied heavily on individual countries' testing strategies. The European Medicines Agency (EMA) was recognized for its swift adaptation to the evolving situation, particularly in evaluating vaccine and drug candidates. However, the EMA faced challenges due to its reliance on clinical trials conducted outside the EU, which underscored the need for better coordination and promotion of pan-European trials. The agency's spokesperson acknowledged the fragmentation of clinical trials as a significant issue that needed addressing. The auditors recommended that both the ECDC and EMA improve their internal processes and collaboration, especially in light of overlapping responsibilities with the newly established Health Emergency Preparedness and Response Authority (HERA). Enhanced coordination among these agencies is essential to ensure a more effective response to future health emergencies. At the start of the pandemic in 2020, the ECDC and EMA had budgets of €61 million and €358 million, respectively, which increased to €90 million and €458 million by 2023. This financial growth reflects the ongoing need for robust public health infrastructure and preparedness in the face of potential future pandemics.